mRNA Cancer Vaccine: How Moderna Used AI to Personalize a Treatment That Succeeded in Phase 3
A personalized mRNA cancer vaccine has just crossed a line cancer researchers have been trying to reach for years. On August 19, 2026, Moderna and Merck announced that intismeran autogene, a made-to-order mRNA treatment combined with Keytruda, met key efficacy endpoints in a large Phase 3 melanoma trial. It reduced the risk of cancer returning … Read more